RLMD

Relmada Therapeutics, Inc. has experienced a significant stock price increase, rising by 1,893.74% over the past year and 51.6% since January 1, 2026, hitting a new 52-week high on May 6, 2026. Positive Phase 2 data for NDV-01 in high-risk NMIBC, showing a 76% complete response rate at 12 months, led to a 25% jump in shares. The company completed a $160 million PIPE financing to support Phase 3 development of NDV-01. The FDA confirmed alignment on the registrational study design for NDV-01 for two separate indications. Relmada Therapeutics is scheduled to report its First Quarter 2026 financial results on May 12, 2026, and hold its 2026 Annual Meeting of Stockholders on May 27, 2026.